Clinical appraisal of abiraterone in the treatment of metastatic prostatic cancer: Patient considerations, novel opportunities, and future directions

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 9-18

  Bedoya, Diego J ^a   Mitsiades, Nicholas ^b,c  

^a Clearview Cancer Institute   (United States)

^b Baylor College of Medicin   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

AKR1C3; Androgen synthesis; CYP17; Dihydrotestosterone; MDV3100(enzalutamide); Testosterone

Indexed keywords

ABIRATERONE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; CABAZITAXEL; CORTICOSTEROID; CYPROTERONE ACETATE; CYTOCHROME P450 17; CYTOCHROME P450 17 INHIBITOR; DEXAMETHASONE; DOCETAXEL; ENZALUTAMIDE; ENZYME INHIBITOR; FLUTAMIDE; GALETERONE; GLUCOCORTICOID; GONADORELIN AGONIST; KETOCONAZOLE; LEUPRORELIN; MINERALOCORTICOID ANTAGONIST; ORTERONEL; PLACEBO; PREDNISONE; PREGNENOLONE; PROSTATE SPECIFIC ANTIGEN; SIPULEUCEL T; STEROIDOGENIC FACTOR 1; UNCLASSIFIED DRUG; UNINDEXED DRUG; VN 124 1;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; AMINOTRANSFERASE BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SYNTHESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AR GENE; BINDING AFFINITY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RESISTANCE; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; DRUG DESIGN; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FLUID RETENTION; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; METASTASIS POTENTIAL; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; PROSTATECTOMY; RECOMMENDED DRUG DOSE; REVIEW; RISK REDUCTION; SIDE EFFECT; SIGNAL TRANSDUCTION; STEROIDOGENESIS; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 84873823561     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S24941     Document Type: Review

References (80)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10-29.
2. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1: 293-297.
3. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2009;10:981-991.
4. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgenresponsive genes and mechanisms of therapy resistance. Am J Pathol. 2004;164:217-227.
5. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castrationresistant prostate cancer. J Clin Oncol. 2009;27:3742-3748.
6. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23:8253-8261.
7. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351:1502-1512.
8. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010;376:1147-1154.
9. Shapiro D, Tareen B. Current and emerging treatments in the management of castration-resistant prostate cancer. Expert Rev Anticancer Ther. 2012;12:951-964.
10. Lheureux S, Joly F. Cabazitaxel after docetaxel: a new option in metastatic castration-resistant prostate cancer. Bull Cancer. 2012;99:875-880. French.
11. Mostaghel EA, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007;67:5033-5041.
12. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008;8:440-448.
13. Scher HI, Buchanan G, Gerald W, Butler LM, Tilley WD. Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. Endocr Relat Cancer. 2004;11:459-476.
14. Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;375:1437-1446.
15. Scott HM, Mason JI, Sharpe RM. Steroidogenesis in the fetal testis and its susceptibility to disruption by exogenous compounds. Endocr Rev. 2009;30:883-925.
16. Payne AH, Hales DB. Overview of steroidogenic enzymes in the pathway from cholesterol to active steroid hormone. Endocr Rev. 2004;25:947-970.
17. Luu-The V, Bélanger A, Labrie F. Androgen biosynthetic pathways in the human prostate. Best Pract Res Clin Endocrinol Metab. 2008;22:207-221.
18. Hoivik EA, Lewis AE, Aumo L, Bakke M. Molecular aspects of steroidogenic factor 1 (SF-1). Mol Cell Endocrinol. 2010;315:27-39.
19. Lin L, Achermann JC. Steroidogenic factor-1 (SF-1, Ad4BP, NR5A1) and disorders of testis development. Sex Dev. 2008;2:200-209.
20. Aesøy R, Mellgren G, Morohashi K, Lund J. Activation of cAMPdependent protein kinase increases the protein level of steroidogenic factor-1. Endocrinology. 2002;143:295-303.
21. Schimmer BP, White PC. Minireview: steroidogenic factor 1: its roles in differentiation, development, and disease. Mol Endocrinol. 2010;24:1322-1337.
22. Penning TM, Byrns MC. Steroid hormone transforming aldo-keto reductases and cancer. Ann N Y Acad Sci. 2009;1155:33-42.
23. Wilbert DM, Griffin JE, Wilson JD. Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab. 1983;56:113-120.
24. Deslypere JP, Young M, Wilson JD, McPhaul MJ. Testosterone and 5 alpha-dihydrotestosterone interact differently with the androgen receptor to enhance transcription of the MMTVCAT reporter gene. Mol Cell Endocrinol. 1992;88:15-22.
25. Ohlson N, Wikström P, Stattin P, Bergh A. Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate. 2005;62:307-315.
26. Gregory CW, Johnson RT Jr, Mohler JL, French FS, Wilson EM. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 2001;61:2892-2898.
27. Pfeiffer MJ, Smit FP, Sedelaar JP, Schalken JA. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol Med. 2011;17:657-664.
28. Mahajan NP, Liu Y, Majumder S, et al. Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation. Proc Natl Acad Sci U S A. 2007;104:8438-8443.
29. Gregory CW, Whang YE, McCall W, et al. Heregulin-induced activation of HER2 and HER3 increases androgen receptor transactivation and CWR-R1 human recurrent prostate cancer cell growth. Clin Cancer Res. 2005;11:1704-1712.
30. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL. HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 2004;6:517-527.
31. Yeh S, Lin HK, Kang HY, Thin TH, Lin MF, Chang C. From HER2/ Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc Natl Acad Sci U S A. 1999;96: 5458-5463.
32. Liu Y, Karaca M, Zhang Z, Gioeli D, Earp HS, Whang YE. Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene. 2008;10:3208-3216.
33. Asim M, Siddiqui IA, Hafeez BB, Baniahmad A, Mukhtar H. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene. 2008;27:3596-3604.
34. O'Malley BW, Kumar R. Nuclear receptor coregulators in cancer biology. Cancer Res. 2009;69:8217-8222.
35. Wu RC, Qin J, Yi P, Wong J, et al. Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic responses to multiple cellular signaling pathways. Mol Cell. 2004;15:937-949.
36. Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68:5469-5477.
37. Hu R, Dunn TA, Wei S, et al. Ligand independent androgen receptor variants derived from splicing of cryptic exons signify hormonerefractory prostate cancer. Cancer Res. 2009;69:16-22.
38. Libertini SJ, Tepper CG, Rodriguez V, Asmuth DM, Kung HJ, Mudryj M. Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence. Cancer Res. 2007;67:9001-9005.
39. Harada N, Inoue K, Yamaji R, Nakano Y, Inui H. Androgen deprivation causes truncation of the C-terminal region of androgen receptor in human prostate cancer LNCaP cells. Cancer Sci. 2012;103:1022-1027.
40. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787-790.
41. Mitsiades N, Chen Y, Scher HI. The AR axis as a pathogenetic mechanism and therapeutic target throughout the clinical states of prostate cancer: opportunities for second-line hormonal manipulations in castration-resistant prostate cancer. In: Scardino PT, Linehan WM, Zelefsky MJ, Vogelzang NJ. Comprehensive Textbook of Genitourinary Oncology, 4th ed. Baltimore: Lippincott Williams & Wilkins; 2011:262-273.
42. Mitsiades N, Sung CC, Schultz N, et al. Distinct Patterns of Dysregulated Expression of Enzymes Involved in Androgen Synthesis and Metabolism in Metastatic Prostate Cancer Tumors. Cancer Res. 2012;72(23):6142-6152.
43. Waltering KK, Helenius MA, Sahu B, et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res. 2009;69:8141-8149.
44. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33-39.
45. Kelly WK, Scher HI. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol. 1993;149:607-609.
46. Klotz L. Maximal androgen blockade for advanced prostate cancer. Best Pract Res Clin Endocrinol Metab. 2008;22:331-340.
47. Pousette A, Carlström K, Stege R. Androgens during different modes of endocrine treatment of prostatic cancer. Urol Res. 1989;17:95-98.
48. Eri LM, Haug E, Tveter KJ. Effects on the endocrine system of longterm treatment with the luteinizing hormone-releasing hormone agonist leuprolide in patients with benign prostatic hyperplasia. Scand J Clin Lab Invest. 1996;56:319-325.
49. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castrationresistant prostate cancer. Cancer Res. 2008;68:6407-6415.
50. Page ST, Lin DW, Mostaghel EA, et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006;91:3850-3856.
51. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res. 2004;10: 7121-7126.
52. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68:4447-4454.
53. Geller J, Albert JD, Nachtsheim DA, Loza D. Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol. 1984;132: 693-696.
54. Mohler JL, Gregory CW, Ford OH 3rd, et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004;10:440-448.
55. Mitsiades N, Schultz N, Taylor BS, et al. Increased expression of androgen receptor (AR) and enzymes involved in androgen synthesis in metastatic prostate cancer: targets for novel personalized therapies. J Clin Oncol. 2009;27:5002.
56. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66:2815-2825.
57. Hofland J, van Weerden WM, Dits NF, et al. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res. 2010;70:1256-1264.
58. Pelletier G. Expression of steroidogenic enzymes and sex-steroid receptors in human prostate. Best Pract Res Clin Endocrinol Metab. 2008;22:223-228.
59. Mostaghel EA, Nelson PS. Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications. Best Pract Res Clin Endocrinol Metab. 2008;22:243-258.
60. Ryan CJ, Halabi S, Ou SS, Vogelzang NJ, Kantoff P, Small EJ. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res. 2007;13:2030-2037.
61. Oh W. Secondary hormonal therapies in the treatment of prostate cancer. Urology. 2002;60 Suppl 3:87-92.
62. Rowlands MG, Barrie SE, Chan F, et al. Esters of 3-pyridylacetic acid that combine potent inhibition of 17 alpha-hydroxylase/C17,20-lyase (cytochrome P450-417alpha) with resistance to esterase hydrolysis. J Med Chem. 1995;38:4191-4197.
63. Food and Drug Administration. Zytiga prescribing information. 2012. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/ label/2012/202379s004 lbl.pdf. Accessed November 27, 2012.
64. Attard G, Belldegrun AS, de Bono JS. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int. 2005;96: 1241-1246.
65. O'Donnell A, Judson I, Dowsett M, et al. Hormonal impact of the 17-hydroxylase/C17,20-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90:2317-2325.
66. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castrationresistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26:4563-4571.
67. Attard G, Reid AH, Auchus RJ, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab. 2012;97:507-516.
68. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxeltreated castration-resistant prostate cancer. J Clin Oncol. 2010;28: 1496-1501.
69. Ryan CJ, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. J Clin Oncol. 2010;28:1481-1488.
70. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364:1995-2005.
71. Ryan CJ, Smith MR, de Bono JS et al Interim analysis (IA) results of COU-AA-302, a randomized, phase III study of abiraterone acetate (AA) in chemotherapy-naive patients (pts) with metastatic castrationresistant prostate cancer (mCRPC). J Clin Oncol. 2012;30:LBA4518.
72. Taplin M, Montgomery RB, Logothetis C, et al. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study. J Clin Oncol. 2012;30:4521.
73. Efstathiou E, Davis JW, Troncoso P, et al. Cytoreduction and androgen signaling modulation by abiraterone acetate (AA) plus leuprolide acetate (LHRHa) versus LHRHa in localized high-risk prostate cancer (PCa): preliminary results of a randomized preoperative study. J Clin Oncol. 2012;30:4556.
74. Petrylak DP, Gandhi JG, Clark WR, et al. Phase I results from a phase I/II study of orteronel, an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castrationresistant prostate cancer (mCRPC). J Clin Oncol. 2012;30:4656.
75. Dreicer R, Agus DB, Bellmunt J, et al. A phase III, randomized, doubleblind, multicenter trial comparing the investigational agent orteronel (TAK-700) plus prednisone (P) with placebo plus P in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy. J Clin Oncol. 2012;30:TPS4693.
76. Sun S, Sprenger CC, Vessella RL, et al. Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest. 2010;120:2715-2730.
77. Hörnberg E, Ylitalo EB, Crnalic S, et al. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PLoS One. 2011;6:e19059.
78. Mostaghel EA, Marck BT, Plymate SR, et al. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res. 2011;17:5913-5925.
79. Cai C, Chen S, Ng P, et al. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res. 2011;71:6503-6513.
80. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367:1187-1197.